25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Aeolus Pharmaceuticl
Buy, Hold or Sell?

Let's analyze Aeolus Pharmaceuticl together

I guess you are interested in Aeolus Pharmaceuticl. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Aeolus Pharmaceuticl. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Aeolus Pharmaceuticl

I send you an email if I find something interesting about Aeolus Pharmaceuticl.

1. Quick Overview

1.1. Quick analysis of Aeolus Pharmaceuticl (30 sec.)










1.2. What can you expect buying and holding a share of Aeolus Pharmaceuticl? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.02
Expected worth in 1 year
$0.13
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
$0.11
Return On Investment
106,255.7%

For what price can you sell your share?

Current Price per Share
$0.00
Expected price per share
$0.0001 - $0.0001
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Aeolus Pharmaceuticl (5 min.)




Live pricePrice per Share (EOD)
$0.00
Intrinsic Value Per Share
$-0.12 - $-0.05
Total Value Per Share
$-0.09 - $-0.02

2.2. Growth of Aeolus Pharmaceuticl (5 min.)




Is Aeolus Pharmaceuticl growing?

Current yearPrevious yearGrowGrow %
How rich?$3.1m-$845k$4m126.4%

How much money is Aeolus Pharmaceuticl making?

Current yearPrevious yearGrowGrow %
Making money-$3.5m-$2.6m-$930k-26.1%
Net Profit Margin-171.4%-84.5%--

How much money comes from the company's main activities?

2.3. Financial Health of Aeolus Pharmaceuticl (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Aeolus Pharmaceuticl?

Welcome investor! Aeolus Pharmaceuticl's management wants to use your money to grow the business. In return you get a share of Aeolus Pharmaceuticl.

First you should know what it really means to hold a share of Aeolus Pharmaceuticl. And how you can make/lose money.

Speculation

The Price per Share of Aeolus Pharmaceuticl is $0.0001. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Aeolus Pharmaceuticl.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Aeolus Pharmaceuticl, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.02. Based on the TTM, the Book Value Change Per Share is $0.03 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.02 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Aeolus Pharmaceuticl.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.04-39,740.7%-0.04-39,740.7%-0.02-17,279.7%-0.01-13,495.0%-0.03-29,013.2%
Usd Book Value Change Per Share0.0326,563.9%0.0326,563.9%-0.02-15,977.8%0.0334,788.2%0.00978.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.0326,563.9%0.0326,563.9%-0.02-15,977.8%0.0334,788.2%0.00978.4%
Usd Price Per Share0.19-0.19-0.24-0.27-0.37-
Price to Earnings Ratio-4.78--4.78--13.92--94.82--33.83-
Price-to-Total Gains Ratio7.15-7.15--15.06-11.31--60.07-
Price to Book Ratio9.04-9.04--43.30-9.47--1.01-
Price-to-Total Gains Ratio7.15-7.15--15.06-11.31--60.07-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0001
Number of shares10000000
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.030.03
Usd Total Gains Per Share0.030.03
Gains per Quarter (10000000 shares)265,639.18347,882.12
Gains per Year (10000000 shares)1,062,556.711,391,528.48
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1010625571062547013915281391518
2021251132125104027830572783046
3031876703187661041745854174574
4042502274250218055661145566102
5053127845312775069576426957630
6063753406375332083491718349158
7074378977437889097406999740686
808500454850044601113222811132214
909563010956300301252375612523742
100106255671062556001391528513915270

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%1.04.00.020.0%2.08.00.020.0%3.018.00.014.3%
Book Value Change Per Share1.00.00.0100.0%2.01.00.066.7%4.01.00.080.0%5.05.00.050.0%10.011.00.047.6%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.021.00.0%
Total Gains per Share1.00.00.0100.0%2.01.00.066.7%4.01.00.080.0%5.05.00.050.0%10.011.00.047.6%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Aeolus Pharmaceuticl compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0270.0270%-0.016+160%0.035-24%0.001+2615%
Book Value Per Share--0.0210.0210%-0.006+126%-0.021+198%-0.044+309%
Current Ratio--4.2544.2540%0.666+539%1.754+143%1.935+120%
Debt To Asset Ratio--0.2330.2330%1.476-84%4.020-94%4.798-95%
Debt To Equity Ratio--0.3040.3040%-+100%0.670-55%0.399-24%
Dividend Per Share----0%-0%-0%-0%
Eps---0.040-0.0400%-0.017-57%-0.013-66%-0.029-27%
Free Cash Flow Per Share---0.020-0.0200%-0.016-21%-0.012-42%-0.014-31%
Free Cash Flow To Equity Per Share--0.0200.0200%-0.009+146%0.003+480%0.000+102%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---0.046--------
Intrinsic Value_10Y_min---0.115--------
Intrinsic Value_1Y_max---0.010--------
Intrinsic Value_1Y_min---0.014--------
Intrinsic Value_3Y_max---0.026--------
Intrinsic Value_3Y_min---0.039--------
Intrinsic Value_5Y_max---0.037--------
Intrinsic Value_5Y_min---0.063--------
Market Cap15208.600-189900%28896340.00028896340.0000%36591891.600-21%40473126.320-29%55672601.160-48%
Net Profit Margin---1.714-1.7140%-0.845-51%-0.630-63%-0.309-82%
Operating Margin---1.577-1.5770%-0.844-46%-0.774-51%-0.555-65%
Operating Ratio--3.9643.9640%2.972+33%2.772+43%1.748+127%
Pb Ratio0.005-189900%9.0449.0440%-43.304+579%9.473-5%-1.010+111%
Pe Ratio-0.003+100%-4.781-4.7810%-13.924+191%-94.822+1883%-33.827+608%
Price Per Share0.000-189900%0.1900.1900%0.241-21%0.266-29%0.366-48%
Price To Free Cash Flow Ratio-0.005+100%-9.294-9.2940%-14.978+61%3.017-408%-13.401+44%
Price To Total Gains Ratio0.004-189900%7.1537.1530%-15.058+311%11.314-37%-60.072+940%
Quick Ratio--4.0174.0170%0.640+527%1.539+161%1.766+127%
Return On Assets---0.854-0.8540%-1.479+73%-0.527-38%-2.019+136%
Return On Equity---1.114-1.1140%--100%-1.143+3%-0.828-26%
Total Gains Per Share--0.0270.0270%-0.016+160%0.035-24%0.001+2615%
Usd Book Value--3195000.0003195000.0000%-845000.000+126%-3139000.000+198%-6670400.000+309%
Usd Book Value Change Per Share--0.0270.0270%-0.016+160%0.035-24%0.001+2615%
Usd Book Value Per Share--0.0210.0210%-0.006+126%-0.021+198%-0.044+309%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.040-0.0400%-0.017-57%-0.013-66%-0.029-27%
Usd Free Cash Flow---3109000.000-3109000.0000%-2443000.000-21%-1815600.000-42%-2144800.000-31%
Usd Free Cash Flow Per Share---0.020-0.0200%-0.016-21%-0.012-42%-0.014-31%
Usd Free Cash Flow To Equity Per Share--0.0200.0200%-0.009+146%0.003+480%0.000+102%
Usd Market Cap15208.600-189900%28896340.00028896340.0000%36591891.600-21%40473126.320-29%55672601.160-48%
Usd Price Per Share0.000-189900%0.1900.1900%0.241-21%0.266-29%0.366-48%
Usd Profit---3558000.000-3558000.0000%-2628000.000-26%-1555200.000-56%-4163900.000+17%
Usd Revenue--2076000.0002076000.0000%3111000.000-33%5207800.000-60%3086000.000-33%
Usd Total Gains Per Share--0.0270.0270%-0.016+160%0.035-24%0.001+2615%
 EOD+2 -6MRQTTM+0 -0YOY+15 -185Y+13 -2010Y+17 -16

3.3 Fundamental Score

Let's check the fundamental score of Aeolus Pharmaceuticl based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.003
Price to Book Ratio (EOD)Between0-10.005
Net Profit Margin (MRQ)Greater than0-1.714
Operating Margin (MRQ)Greater than0-1.577
Quick Ratio (MRQ)Greater than14.017
Current Ratio (MRQ)Greater than14.254
Debt to Asset Ratio (MRQ)Less than10.233
Debt to Equity Ratio (MRQ)Less than10.304
Return on Equity (MRQ)Greater than0.15-1.114
Return on Assets (MRQ)Greater than0.05-0.854
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of Aeolus Pharmaceuticl based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than500.000
Ma 20Greater thanMa 500.000
Ma 50Greater thanMa 1000.000
Ma 100Greater thanMa 2000.000
OpenGreater thanClose0.000
Total0/5 (0.0%)

4. In-depth Analysis

4.1 About Aeolus Pharmaceuticl

Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, as well as AEOL 20415 for treating infectious diseases. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.

Fundamental data was last updated by Penke on 2024-09-19 18:35:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Aeolus Pharmaceuticl earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Aeolus Pharmaceuticl to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -171.4% means that $-1.71 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Aeolus Pharmaceuticl:

  • The MRQ is -171.4%. The company is making a huge loss. -2
  • The TTM is -171.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-171.4%TTM-171.4%0.0%
TTM-171.4%YOY-84.5%-86.9%
TTM-171.4%5Y-63.0%-108.4%
5Y-63.0%10Y-30.9%-32.1%
4.3.1.2. Return on Assets

Shows how efficient Aeolus Pharmaceuticl is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Aeolus Pharmaceuticl to the Drug Manufacturers - Specialty & Generic industry mean.
  • -85.4% Return on Assets means that Aeolus Pharmaceuticl generated $-0.85 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Aeolus Pharmaceuticl:

  • The MRQ is -85.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -85.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-85.4%TTM-85.4%0.0%
TTM-85.4%YOY-147.9%+62.5%
TTM-85.4%5Y-52.7%-32.7%
5Y-52.7%10Y-201.9%+149.2%
4.3.1.3. Return on Equity

Shows how efficient Aeolus Pharmaceuticl is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Aeolus Pharmaceuticl to the Drug Manufacturers - Specialty & Generic industry mean.
  • -111.4% Return on Equity means Aeolus Pharmaceuticl generated $-1.11 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Aeolus Pharmaceuticl:

  • The MRQ is -111.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -111.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-111.4%TTM-111.4%0.0%
TTM-111.4%YOY--111.4%
TTM-111.4%5Y-114.3%+2.9%
5Y-114.3%10Y-82.8%-31.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Aeolus Pharmaceuticl.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Aeolus Pharmaceuticl is operating .

  • Measures how much profit Aeolus Pharmaceuticl makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Aeolus Pharmaceuticl to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of -157.7% means the company generated $-1.58  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Aeolus Pharmaceuticl:

  • The MRQ is -157.7%. The company is operating very inefficient. -2
  • The TTM is -157.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-157.7%TTM-157.7%0.0%
TTM-157.7%YOY-84.4%-73.2%
TTM-157.7%5Y-77.4%-80.3%
5Y-77.4%10Y-55.5%-21.8%
4.3.2.2. Operating Ratio

Measures how efficient Aeolus Pharmaceuticl is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 3.96 means that the operating costs are $3.96 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Aeolus Pharmaceuticl:

  • The MRQ is 3.964. The company is inefficient in keeping operating costs low. -1
  • The TTM is 3.964. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ3.964TTM3.9640.000
TTM3.964YOY2.972+0.992
TTM3.9645Y2.772+1.192
5Y2.77210Y1.748+1.024
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Aeolus Pharmaceuticl.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Aeolus Pharmaceuticl is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 4.25 means the company has $4.25 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Aeolus Pharmaceuticl:

  • The MRQ is 4.254. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.254. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.254TTM4.2540.000
TTM4.254YOY0.666+3.589
TTM4.2545Y1.754+2.500
5Y1.75410Y1.935-0.180
4.4.3.2. Quick Ratio

Measures if Aeolus Pharmaceuticl is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Aeolus Pharmaceuticl to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 4.02 means the company can pay off $4.02 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Aeolus Pharmaceuticl:

  • The MRQ is 4.017. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.017. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.017TTM4.0170.000
TTM4.017YOY0.640+3.377
TTM4.0175Y1.539+2.479
5Y1.53910Y1.766-0.227
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Aeolus Pharmaceuticl.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Aeolus Pharmaceuticl assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Aeolus Pharmaceuticl to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.23 means that Aeolus Pharmaceuticl assets are financed with 23.3% credit (debt) and the remaining percentage (100% - 23.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Aeolus Pharmaceuticl:

  • The MRQ is 0.233. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.233. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.233TTM0.2330.000
TTM0.233YOY1.476-1.242
TTM0.2335Y4.020-3.786
5Y4.02010Y4.798-0.779
4.5.4.2. Debt to Equity Ratio

Measures if Aeolus Pharmaceuticl is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Aeolus Pharmaceuticl to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 30.4% means that company has $0.30 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Aeolus Pharmaceuticl:

  • The MRQ is 0.304. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.304. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.304TTM0.3040.000
TTM0.304YOY-+0.304
TTM0.3045Y0.670-0.366
5Y0.67010Y0.399+0.272
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Aeolus Pharmaceuticl generates.

  • Above 15 is considered overpriced but always compare Aeolus Pharmaceuticl to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -4.78 means the investor is paying $-4.78 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Aeolus Pharmaceuticl:

  • The EOD is -0.003. Based on the earnings, the company is expensive. -2
  • The MRQ is -4.781. Based on the earnings, the company is expensive. -2
  • The TTM is -4.781. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.003MRQ-4.781+4.778
MRQ-4.781TTM-4.7810.000
TTM-4.781YOY-13.924+9.143
TTM-4.7815Y-94.822+90.041
5Y-94.82210Y-33.827-60.995
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Aeolus Pharmaceuticl:

  • The EOD is -0.005. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -9.294. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -9.294. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.005MRQ-9.294+9.290
MRQ-9.294TTM-9.2940.000
TTM-9.294YOY-14.978+5.684
TTM-9.2945Y3.017-12.311
5Y3.01710Y-13.401+16.418
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Aeolus Pharmaceuticl is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Aeolus Pharmaceuticl:

  • The EOD is 0.005. Based on the equity, the company is cheap. +2
  • The MRQ is 9.044. Based on the equity, the company is overpriced. -1
  • The TTM is 9.044. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD0.005MRQ9.044-9.039
MRQ9.044TTM9.0440.000
TTM9.044YOY-43.304+52.348
TTM9.0445Y9.473-0.429
5Y9.47310Y-1.010+10.483
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2016-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets4,167
Total Liabilities972
Total Stockholder Equity3,195
 As reported
Total Liabilities 972
Total Stockholder Equity+ 3,195
Total Assets = 4,167

Assets

Total Assets4,167
Total Current Assets4,135
Long-term Assets32
Total Current Assets
Cash And Cash Equivalents 3,155
Net Receivables 750
Other Current Assets 230
Total Current Assets  (as reported)4,135
Total Current Assets  (calculated)4,135
+/-0
Long-term Assets
Long Term Investments 32
Long-term Assets  (as reported)32
Long-term Assets  (calculated)32
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities972
Long-term Liabilities0
Total Stockholder Equity3,195
Total Current Liabilities
Accounts payable 972
Total Current Liabilities  (as reported)972
Total Current Liabilities  (calculated)972
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock1,520
Retained Earnings -190,188
Capital Surplus 191,863
Total Stockholder Equity (as reported)3,195
Total Stockholder Equity (calculated)3,195
+/-0
Other
Cash and Short Term Investments 3,155
Common Stock Shares Outstanding 148,668
Common Stock Total Equity1,520
Liabilities and Stockholders Equity 4,167
Net Debt -3,155
Net Tangible Assets 3,195
Net Working Capital 3,163



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2016-09-302015-09-302014-09-302013-09-302012-09-302011-09-302010-09-302009-09-302008-09-302007-09-302006-09-302005-09-302004-09-302003-09-302002-09-302001-09-302000-09-301999-09-301998-09-301997-09-301996-09-30
> Total Assets 
38,900
38,500
27,800
8,000
7,348
8,618
2,201
1,080
7,856
937
3,554
1,931
1,120
811
2,433
2,290
1,256
1,966
3,580
1,777
4,167
4,1671,7773,5801,9661,2562,2902,4338111,1201,9313,5549377,8561,0802,2018,6187,3488,00027,80038,50038,900
   > Total Current Assets 
37,100
36,200
21,200
5,500
7,155
6,921
593
700
7,630
929
3,428
1,806
555
779
2,401
2,258
1,224
1,935
3,548
1,745
4,135
4,1351,7453,5481,9351,2242,2582,4017795551,8063,4289297,6307005936,9217,1555,50021,20036,20037,100
       Cash And Cash Equivalents 
21,400
17,600
10,600
2,400
1,877
5,453
209
586
7,381
626
3,324
1,727
399
646
2,355
518
281
869
1,517
94
3,155
3,155941,5178692815182,3556463991,7273,3246267,3815862095,4531,8772,40010,60017,60021,400
       Short-term Investments 
0
0
0
2,600
4,678
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000004,6782,600000
       Net Receivables 
1,400
1,100
1,100
300
197
1,175
293
0
131
14
0
0
0
0
0
1,677
882
370
1,559
1,585
750
7501,5851,5593708821,677000001413102931,1751973001,1001,1001,400
       Other Current Assets 
14,300
17,500
9,500
200
403
293
91
114
118
289
104
79
156
133
46
63
61
656
426
21
230
2302142665661634613315679104289118114912934032009,50017,50014,300
   > Long-term Assets 
1,800
2,300
6,600
2,500
193
1,697
1,608
380
226
8
126
125
565
32
32
32
32
31
32
32
32
323232313232323256512512682263801,6081,6971932,5006,6002,3001,800
       Property Plant Equipment 
300
300
3,000
2,500
193
1,341
1,252
25
15
0
0
0
0
0
0
0
0
0
0
0
0
00000000000015251,2521,3411932,5003,000300300
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
32
0
32
32
32
32
32323232032000000000000000
       Long-term Assets Other 
1,500
2,000
3,600
0
0
356
356
355
211
0
0
0
0
0
0
0
0
0
0
0
0
000000000000211355356356003,6002,0001,500
> Total Liabilities 
2,000
12,000
8,100
4,200
2,536
2,971
16,681
18,159
2,324
1,869
1,847
751
2,157
1,968
29,169
25,549
21,591
1,261
1,995
2,622
972
9722,6221,9951,26121,59125,54929,1691,9682,1577511,8471,8692,32418,15916,6812,9712,5364,2008,10012,0002,000
   > Total Current Liabilities 
2,000
11,800
6,600
3,300
2,493
2,954
2,183
2,942
1,537
1,002
1,847
268
1,891
774
1,620
2,144
2,272
1,261
1,995
2,622
972
9722,6221,9951,2612,2722,1441,6207741,8912681,8471,0021,5372,9422,1832,9542,4933,3006,60011,8002,000
       Short-term Debt 
0
100
800
700
49
25
193
2,048
0
0
956
0
534
0
663
0
0
0
0
1,002
0
01,002000066305340956002,04819325497008001000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,002
0
01,0020000000000000000000
       Accounts payable 
200
400
2,600
700
637
1,437
1,368
461
1,185
712
868
266
991
774
957
2,144
2,272
579
1,552
1,598
972
9721,5981,5525792,2722,1449577749912668687121,1854611,3681,4376377002,600400200
       Other Current Liabilities 
1,800
11,300
3,200
1,900
1,807
969
245
388
352
290
23
2
366
0
957
0
0
579
1,552
1,598
0
01,5981,5525790095703662232903523882459691,8071,9003,20011,3001,800
   > Long-term Liabilities 
0
200
1,500
900
43
17
14,498
15,217
787
867
0
483
266
1,194
27,549
23,405
19,319
0
0
0
0
000019,31923,40527,5491,194266483086778715,21714,49817439001,5002000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
30
0
0
27,549
23,405
19,319
0
0
0
0
000019,31923,40527,549003000000000000
> Total Stockholder Equity
36,200
26,500
19,700
3,800
4,812
5,647
-14,480
-17,079
5,532
-932
1,707
1,180
-1,037
-1,157
-26,736
-23,259
-20,335
705
1,585
-845
3,195
3,195-8451,585705-20,335-23,259-26,736-1,157-1,0371,1801,707-9325,532-17,079-14,4805,6474,8123,80019,70026,50036,200
   Common Stock
0
0
0
0
7
13
14
14
139
140
293
320
320
376
568
605
627
1,346
1,359
1,359
1,520
1,5201,3591,3591,34662760556837632032029314013914141370000
   Retained Earnings -190,188-186,630-184,002-183,922-180,714-182,412-182,711-161,195-158,899-155,926-152,902-147,093-140,188-122,886-118,961-106,772-83,907-77,200-57,600-13,400-3,300
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
158,543
0
0
184,223
184,421
191,863
191,863184,421184,22300158,543000000000000000
   Treasury Stock000000000000000000000
   Other Stockholders Equity 
39,500
39,900
77,300
81,700
88,951
112,516
104,679
105,892
145,576
146,016
154,311
156,781
157,573
159,657
155,402
158,543
159,747
183,276
184,223
184,421
191,863
191,863184,421184,223183,276159,747158,543155,402159,657157,573156,781154,311146,016145,576105,892104,679112,51688,95181,70077,30039,90039,500



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-09-30. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue-
Cost of Revenue--
Gross Profit-0
 
Operating Income (+$)
Gross Profit-
Operating Expense--
Operating Income-0
 
Operating Expense (+$)
Research Development-
Selling General Administrative-
Selling And Marketing Expenses-
Operating Expense-0
 
Net Interest Income (+$)
Interest Income-
Interest Expense--
Other Finance Cost-0
Net Interest Income-
 
Pretax Income (+$)
Operating Income-
Net Interest Income-
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-0
EBIT - interestExpense = 0
0
0
Interest Expense-
Earnings Before Interest and Taxes (EBIT)-0
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-
Tax Provision--
Net Income From Continuing Ops-0
Net Income-
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-0
 

Technical Analysis of Aeolus Pharmaceuticl
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Aeolus Pharmaceuticl. The general trend of Aeolus Pharmaceuticl is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Aeolus Pharmaceuticl's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Aeolus Pharmaceuticl.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 0.0001 < 0.0001 < 0.0001.

The bearish price targets are: 0.0001 > 0.0001 > 0.0001.

Tweet this
Aeolus Pharmaceuticl Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Aeolus Pharmaceuticl. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Aeolus Pharmaceuticl Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Aeolus Pharmaceuticl. The current macd is 0.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Aeolus Pharmaceuticl price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Aeolus Pharmaceuticl. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Aeolus Pharmaceuticl price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Aeolus Pharmaceuticl Daily Moving Average Convergence/Divergence (MACD) ChartAeolus Pharmaceuticl Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Aeolus Pharmaceuticl. The current adx is 99.99.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Aeolus Pharmaceuticl Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Aeolus Pharmaceuticl. The current sar is 0.00010003.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Aeolus Pharmaceuticl Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Aeolus Pharmaceuticl. The current rsi is 0. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 1/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
Aeolus Pharmaceuticl Daily Relative Strength Index (RSI) ChartAeolus Pharmaceuticl Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Aeolus Pharmaceuticl. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Aeolus Pharmaceuticl price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Aeolus Pharmaceuticl Daily Stochastic Oscillator ChartAeolus Pharmaceuticl Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Aeolus Pharmaceuticl. The current cci is -66.66666667.

Aeolus Pharmaceuticl Daily Commodity Channel Index (CCI) ChartAeolus Pharmaceuticl Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Aeolus Pharmaceuticl. The current cmo is 0.

Aeolus Pharmaceuticl Daily Chande Momentum Oscillator (CMO) ChartAeolus Pharmaceuticl Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Aeolus Pharmaceuticl. The current willr is 0.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Aeolus Pharmaceuticl Daily Williams %R ChartAeolus Pharmaceuticl Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Aeolus Pharmaceuticl.

Aeolus Pharmaceuticl Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Aeolus Pharmaceuticl. The current atr is 0.

Aeolus Pharmaceuticl Daily Average True Range (ATR) ChartAeolus Pharmaceuticl Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Aeolus Pharmaceuticl. The current obv is 0.

Aeolus Pharmaceuticl Daily On-Balance Volume (OBV) ChartAeolus Pharmaceuticl Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Aeolus Pharmaceuticl. The current mfi is 0.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Aeolus Pharmaceuticl Daily Money Flow Index (MFI) ChartAeolus Pharmaceuticl Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Aeolus Pharmaceuticl.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal

6.3. Candlestick Patterns

Aeolus Pharmaceuticl Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Aeolus Pharmaceuticl based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than500.000
Ma 20Greater thanMa 500.000
Ma 50Greater thanMa 1000.000
Ma 100Greater thanMa 2000.000
OpenGreater thanClose0.000
Total0/5 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Aeolus Pharmaceuticl with someone you think should read this too:
  • Are you bullish or bearish on Aeolus Pharmaceuticl? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Aeolus Pharmaceuticl? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Aeolus Pharmaceuticl

I send you an email if I find something interesting about Aeolus Pharmaceuticl.


Comments

How you think about this?

Leave a comment

Stay informed about Aeolus Pharmaceuticl.

Receive notifications about Aeolus Pharmaceuticl in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.